Veritas Pharma Inc Closes On Its Acquisition Of Cannevert Therapeutics Ltd.

ID: 1499730
recent pressrelease next pressrelease

(businesspress24) -
VERITAS PHARMA INC CLOSES ON ITS ACQUISITION OF CANNEVERT THERAPEUTICS LTD

April 21, 2017, Vancouver, B.C. - Veritas Pharma Inc. (VRT or the Company) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) announces that, further to its December 21, 2015 and October 5, 2016 news releases, it has paid the final installment for its acquisition of 80% of the issued and outstanding shares in Cannevert Therapeutics Ltd. ("CTL or Cannevert"), and the Company will enter into a second amending agreement (the Second Amending Agreement) with respect to the existing share purchase agreement with Cannevert.

Pursuant to the Second Amending Agreement, the Company and Cannevert will engage an independent business valuator within 90 days to report on the value of Cannevert. The Company will provide a future update once a valuator has been appointed.

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTLs unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The companys commercial mission is to patent protect CTLs IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

About Cannevert Therapeutics Ltd.

CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. Veritas has advanced $1.5 million to CTL and holds an 80% ownership interest in CTL. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.



Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors; Veritas Pharma Inc.

"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir(at)veritaspharmainc.com
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Forward Looking Statements

This news release contains forward-looking statements and other statements that are not historical facts including statements about the above-description acquisition, the appointment of an independent business valuator, and ongoing plans regarding the combined operations of the Company and Cannevert. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to vary materially from target results or events predicted in these forward-looking statements. As a result, investors are cautioned not to place undue reliance on these forward-looking statements.

The forward-looking statements contained in this news release are made as of the date of this release. Except as required by applicable law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking information reflects the current expectations or belief of the Company based on information currently available and such information is subject to a number of assumptions, risks and uncertainties.






More information:
http:// https://thelaurenashtyncollection.com/ https://www.optegra.com https://cherrystoneauctions.com



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:





PressContact / Agency:



published by: irw
print pressrelease  send to a friend  

Date: 04/21/2017 - 03:43
Language: English
News-ID 1499730
Character count: 6301
Kontakt-Informationen:
Firma: Veritas Pharma Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Wien
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 175

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 8 000
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 90


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.